on STIMVIA
Stimvia Expands Team to Drive Global Growth of URIS® Therapy
Stimvia, a Czech medical technology firm specializing in non-invasive neuromodulation therapies for overactive bladder, has bolstered its Scientific Advisory Board and commercial leadership. This move supports the global expansion of its flagship URIS® therapy.
The Advisory Board now includes prominent urology experts from the United States, United Kingdom, and Europe. These additions aim to strengthen the company's clinical and scientific leadership and facilitate international market expansion. Notable members include Dr. David R. Staskin from Boston, Prof. Alan J. Wein, Prof. Christopher R. Chapple, and Prof. Bertil Blok.
On the commercial front, Dr. David da Silva and Alim Topdag have joined to lead global distribution and sales efforts. Their experience is expected to aid Stimvia's growth in Europe, LATAM, and beyond, ensuring the international success of URIS®.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all STIMVIA news